Release Date: November 12, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• CareCloud Inc (NASDAQ:CCLD) has fully paid down over $10 million in credit line, showcasing strong financial management.
• The company plans to resume monthly dividend payments on its preferred shares starting March 2025, indicating confidence in profitability.
• CareCloud Inc (NASDAQ:CCLD) reported a 111% increase in adjusted EBITDA year-over-year, reaching $6.8 million.
• The company achieved a 328% improvement in year-to-date free cash flow compared to 2023.
• CareCloud Inc (NASDAQ:CCLD) is advancing its AI solutions, which streamline administrative tasks and improve clinical efficiency.

Negative Points

• Revenue for Q3 2024 was $28.5 million, slightly down from $29.3 million in Q3 2023.
• The company faces challenges in predicting revenue from its MESR division due to fluctuations in non-recurring revenue.
• CareCloud Inc (NASDAQ:CCLD) had to reduce its reliance on third-party contractors, indicating potential past inefficiencies.
• The company experienced a decline in non-recurring professional services revenues from MESR, dropping from $5 million to $4.3 million.
• There is modest revenue from AI solutions, suggesting that these products are still in early stages of monetization.

Q & A Highlights

• Warning! GuruFocus has detected 4 Warning Signs with CCLD.

Q: Can you provide more insight into your life science partnerships and what types of companies you are working with? A: We have initiated partnerships, such as with Doy, focusing on medication adherence. We analyze patient-specific data to recommend medications and provide information like available coupons. Our extensive data asset, built over 20 years, is valuable for life sciences partners for risk assessment and research. While revenue from these partnerships isn't separately identified yet, we expect it to contribute to our revenue goals next year. - Unidentified_9

Q: What is the current status of your AI services rollout, and what are the early indications from clients? A: We initially offered a 30 to 60-day trial for our AI services, such as CAI Notes, which have been enhanced to convert conversations into structured charts and suggest diagnoses. We have started converting trial users into paying clients. While revenue is modest, the client base using AI features has grown to over 100 users, with a subset paying for the services. - Unidentified_9

Q: Regarding MEDSR, is there any indication that its revenue might be bottoming or has potential for growth? A: MEDSR's revenue is challenging to predict due to past issues with Epic-related services. We hope to enter 2025 with a similar backlog as last year, but this doesn't guarantee hitting the same revenue numbers. We'll provide updates as we approach year-end and set guidance for next year. - Unidentified_9

Q: Are you still on track to achieve the $26 million in expense cuts you identified, and how much of that will be realized this year? A: We are confident in achieving the $26 million in expense cuts by year-end, with about $20 million realized this year. These reductions come from utilizing proprietary technology, reducing reliance on third-party contractors, and leveraging our global business model. - Unidentified_11

Q: Can you provide an update on your remote patient monitoring (RPM) solution and its outlook? A: We have launched our in-house RPM solution, which offers better margins and client service compared to our previous third-party partnership. For the first nine months of 2024, RPM generated $544,000 in revenue. We expect significant growth in this area as we leverage our core technology strengths. - Unidentified_11

For the complete transcript of the earnings call, please refer to the full earnings call transcript.